Core Viewpoint - The company has observed an increase in share price and trading volume on specific dates in late October and early November 2025, but the board is unaware of any reasons for these changes or any undisclosed information that could affect the market [1] Group 1 - The board confirmed that the company's business operations remain normal and that there have been no significant changes in the business or financial status as of the announcement date [1] - A wholly-owned subsidiary, Shanxi Tuo Yun Biotechnology Co., Ltd., signed a strategic cooperation agreement on October 23, 2025, with three companies for a procurement deal valued at no less than RMB 1 billion for Rhizoclonium and related products from 2026 to 2028 [1] - The specific commercial terms such as pricing, quantity, and delivery methods are yet to be negotiated, and a formal procurement agreement has not been signed [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Touyun Biotech Group Limited 董事會欣然向本公司股東及潛在投資者提供業務更新：本公司之全資附屬公司山 西透雲生物科技有限公司（「山西透雲」）已於2025年10月23日與深圳樓宇間供應鏈 科技股份有限公司 、 河南國字頭營銷管理有限公司及北京合萬家生物科技有限公 司（ 統稱「銷售聯合體」）簽署一份戰略合作協議（「戰略合作協議」）。根據該戰略合 作協議，於2026年至2028年期間，銷售聯合體將向山西透雲採購總值不低於人民 – 1 – 幣10億元的萊茵衣藻及相關產品。具體商業條款如售價、數量及交付方式等須待 訂約各方進一步磋商，尚未簽署正式採購協議。此戰略合作協議屬本集團為其萊 茵衣藻產品系列探索市場機遇之日常業務運作的一部分。 由於該戰略合作協議所擬進行之交易可能會亦可能不會落實，本公司股東及潛在 投資者於買賣本 ...

Summary of Key Points Core Viewpoint - As of November 3, 64 stocks reached their 52-week highs, with notable performers including Zhi'ao Holdings (08581), Tuo Yun Bio (01332), and New Silk Road Cultural Tourism (00472), achieving high rates of 547.06%, 89.87%, and 66.67% respectively [1]. 52-Week Highs - Zhi'ao Holdings (08581) closed at 0.136, with a peak price of 0.440, marking a high rate of 547.06% [1]. - Tuo Yun Bio (01332) closed at 0.500, reaching a maximum of 0.750, reflecting a high rate of 89.87% [1]. - New Silk Road Cultural Tourism (00472) closed at 0.345, with a peak of 0.500, achieving a high rate of 66.67% [1]. - Other notable stocks include Qianbadu (01028) at 60.38% and China Shangcheng (02330) at 31.25% [1]. 52-Week Lows - Hengda Group Holdings (03616) reached a low of 0.255, reflecting a decline of 15.00% [2]. - Feitian Yundong (06610) closed at 0.138, with a decrease of 13.33% [2]. - Huaxia SOL-R (83460) recorded a low of 6.525, down by 13.00% [2]. - Other significant declines include XINAN Samsung-U (09347) at -11.93% and Jinye Holdings (08356) at -10.26% [2]. Stock Performance - The performance of stocks varied significantly, with some stocks like Zhi'ao Holdings showing remarkable growth while others like Hengda Group Holdings faced substantial declines [1][2]. - The overall market sentiment appears to be mixed, with a notable number of stocks reaching new highs amidst some experiencing significant lows [1][2].

Group 1 - The stock of Touyun Biotechnology (01332.HK) has surged over 81%, reaching an intraday high of 0.75 HKD, which represents an almost 900% increase from the opening price of 0.076 HKD on October 30 [1] - As of the time of reporting, the stock is up 45.45%, trading at 0.56 HKD, with a trading volume of 15.593 million HKD [1]

Core Viewpoint - Tongyun Biotechnology (01332) has seen a significant stock price increase of over 81%, reaching a peak of 0.75 HKD, which represents an almost 900% rise from the opening price of 0.076 HKD on October 30 [1] Company Summary - Tongyun Biotechnology is a wholly-owned subsidiary of Hong Kong-listed Tongyun Biotechnology Group, established in 2020 in Lucheng District, Shanxi Province, with an investment of 370 million HKD to build the world's first large-scale production facility for Rhizoclonium algae [1] - The company has a planned annual production capacity of 20,000 tons of Rhizoclonium algae powder, with the first phase of 4,000 tons having commenced production three months ahead of schedule in March 2023, utilizing a unique acetic acid fermentation process for automated production [1] Strategic Partnership - On October 24, Tongyun Biotechnology signed a strategic cooperation agreement with a sales consortium consisting of Shenzhen Building Supply Chain Technology Co., Ltd., Henan Guozi Marketing Management Co., Ltd., and Beijing He Wan Jia Biotechnology Co., Ltd. [1] - According to the agreement, the consortium will purchase no less than 1 billion HKD worth of Rhizoclonium algae products from Tongyun Biotechnology between 2026 and the end of 2028 [1]

Core Viewpoint - Tuo Yun Bio (01332) has seen a significant stock price increase of nearly 900% since October 30, with a peak of 0.75 HKD and a current price of 0.56 HKD, driven by a strategic partnership agreement for substantial product procurement [1] Company Summary - Shanxi Tuo Yun Bio Technology Co., Ltd., a wholly-owned subsidiary of Tuo Yun Bio Group, has signed a strategic cooperation agreement with a sales consortium for the procurement of no less than 1 billion RMB worth of Rhizoclonium algae products from 2026 to 2028 [1] - The company is recognized as a key project and high-tech enterprise in Shanxi Province, having established the world's first large-scale production facility for Rhizoclonium algae with an investment of 370 million RMB [1] - The facility, located in Lucheng District, is designed to produce 20,000 tons of Rhizoclonium algae powder annually, with the first phase of 4,000 tons having commenced production three months ahead of schedule in March 2023 [1] Industry Summary - The strategic partnership highlights the growing demand for microalgae products, which are increasingly recognized for their potential in various applications, including health and nutrition [1] - The use of proprietary acetic acid fermentation technology in a closed automated production process addresses traditional challenges in the microalgae industry, such as land use and pollution [1]

Core Viewpoint - The stock of Touyun Biotechnology (01332) surged over 70% following the announcement of a strategic cooperation agreement worth at least 1 billion yuan for the procurement of its products from 2026 to 2028 [1] Company Summary - Touyun Biotechnology, a subsidiary of Hong Kong-listed Touyun Biotechnology Group, focuses on developing advanced fermentation technology to produce green food, specifically the Rhenish algae [1] - The recent strategic cooperation agreement marks a significant milestone for the commercialization of Rhenish algae, indicating the company's transition into a phase of large-scale commercial realization [1] Industry Summary - The agreement involves a sales consortium consisting of Shenzhen Building Supply Chain Technology Co., Ltd., Henan Guozi Marketing Management Co., Ltd., and Beijing He Wan Jia Biotechnology Co., Ltd., highlighting a collaborative effort in the industry [1] - The procurement agreement is set to enhance the market presence of Rhenish algae products, potentially leading to increased demand and growth within the green food sector [1]

透云生物(01332)午后飙升逾70%，截至发稿，涨51.59%，报0.191港元，成交额369.99万港元。 消息面上，据长治日报报道，10月24日，山西透云生物科技有限公司，与由深圳楼宇间供应链科技股份 有限公司、河南国字头营销管理有限公司、北京合万家生物科技有限公司组成的销售联合体签署战略合 作协议。根据协议，2026年至2028年底，该联合体将采购透云生物价值不低于10亿元的莱茵衣藻系列产 品。 公开资料显示，山西透云生物致力于研发先进的发酵技术来生产新世纪的绿色食物——莱茵衣藻。该公 司是香港上市公司透云生物集团全资子公司。此次山西透云生物签下10亿元战略合作协议，标志着莱茵 衣藻正式迈入了规模化商业变现的收获期。 ...

公司名稱: 透雲生物科技集團有限公司 呈交日期: 2025年10月3日 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01332 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 | ...

Touyun Biotech Group Limited 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司股東及潛在投資者於買賣本公司證券時應審慎行事。 承董事會命 透 雲 生 物 科 技 集 團 有 限 公 司 （於百慕達註冊成立的有限公司） （股份代號：1332） 有關解決核數保留意見行動計劃執行情況的季度更新 本 公 告 乃 由 透 雲 生 物 科 技 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）董事（「董事」）會（「董事會」）根據香港聯合交易所有限公司證券上市規則（「上 市規則」）第13.09 (2)條及香港法例第571章證券及期貨條例第XIVA部內幕消息條文 （ 定義見上市規則 ）而作出。 茲 提 述 本 公 司 截 至 2024 年 12 月 31 日 止 年 度 的 年 報（「 2024 年 年 報 」）。 除 ...